Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adjuvant Dabrafenib in Stage IIIC Melanoma
NCT01682213Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Sep 2012
- Primary completion
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of dabrafenib + trametinib in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Sep 2012; status: completed.
02
Drugs
dabrafenib + trametinib
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT01682213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01682213.